There is wide variation in the use of thrombolytic therapy for myocardial infarction across UK hospitals, largely driven by differing thresholds for applying clinical contraindications related to hemorrhagic risk.
No takes yet. Share an insight, caveat, or question.
Wide variation in thrombolysis for MI across hospitals may reflect inconsistent contraindication thresholds; leaves open need for standardized criteria and outcome studies.
John Birkhead (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: